Ricevi le ultime notizie sulle azioni Arcutis Biotherapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ARQT

Ultime notizie per

ARCUTIS BIOTHERAPEUTICS INC

Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Elevate,Healthcare,With,Ai,Technology,Services.virtual,Health,Care,Analytics,Empower

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

ARQT

TNXP

L&#39;analisi tecnica rivela segnali di allarme per queste società: cosa devono aspettarsi gli investitori e perché è importante agire.

2 titoli del settore sanitario che potrebbero crollare questo trimestre

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics Inc

Press Releases

Arcutis to Present at Upcoming Investor Conferences

Management

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biotech Movers: Four Companies Making Big Strides in Innovation and Growth (MDCX, ARQT, CRMD, MCXT)

Allure Magazine Honors Arcutis' ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

Health Care

Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025

Financing

FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

CRMD

MDCX

MXCT

PVLA

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Alvotech

Beam Therapeutics

Cidara Therapeutics

Celcuity

Cogent Biosciences

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Denali Therapeutics

Dyne Therapeutics

89bio

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

ImmunityBio

IDEAYA Biosciences

Immunovant

Disc Medicine

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mesoblast Limited - American Depositary Shares

Mesoblast

NuCana

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Veracyte

Needham

Goldman Sachs

HC Wainwright & Co.

Jefferies

Comments

Arcutis Biotherapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO